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Introduction: The complement system is essential for an adequate immune response.
Much attention has been given to the role of complement in disease. However, to
better understand complement in pathology, it is crucial to first analyze this system
under different physiological conditions. The aim of the present study was therefore to
investigate the inter-individual variation in complement activity and the influences of age
and sex.
Methods: Complement levels and functional activity were determined in 120 healthy
volunteers, 60 women, 60 men, age range 20–69 year. Serum functional activity of the
classical pathway (CP), lectin pathway activated by mannan (MBL-LP) and alternative
pathway (AP) was measured in sera, using deposition of C5b-9 as readout. In addition,
levels of C1q, MBL, MASP-1, MASP-2, ficolin-2, ficolin-3, C2, C4, C3, C5, C6, C7, C8,
C9, factor B, factor D, properdin, C1-inhibitor and C4b-binding protein, were determined.
Age- and sex-related differences were evaluated.
Results: Significantly lower AP activity was found in females compared to males. Further
analysis of the AP revealed lower C3 and properdin levels in females, while factor D
concentrations were higher. MBL-LP activity was not influenced by sex, but MBL and
ficolin-3 levels were significantly lower in females compared to males. There were no
significant differences in CP activity or CP components between females and males,
nevertheless females had significantly lower levels of the terminal components. The CP
and AP activity was significantly higher in the elderly, in contrast to MBL-LP activity.
Moreover, C1-inhibitor, C5, C8, and C9 increased with age in contrast to a decrease
of factor D and C3 levels. In-depth analysis of the functional activity assays revealed
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that MBL-LP activity was predominantly dependent on MBL and MASP-2 concentration,
whereas CP activity relied on C2, C1-inhibitor and C5 levels. AP activity was strongly and
directly associated with levels of C3, factor B and C5.
Conclusion: This study demonstrated significant sex and age-related differences
in complement levels and functionality in the healthy population. Therefore, age and
sex analysis should be taken into consideration when discussing complement-related
pathologies and subsequent complement-targeted therapies.
Keywords: complement, health, sex and age, innate imunity, gender
INTRODUCTION
The complement system, a major component of innate
immunity, plays a crucial role in the immune response. In health,
maintaining a balance between activation and inhibition of the
complement system is key to preserve tissue homeostasis and
to enable immune surveillance (1, 2). However, an overactive
system can cause autoimmune and inflammatory diseases,
whereas an inactive complement system results in an increased
risk for infection. Several elements can disrupt this delicate
balance and with age these effects are exacerbated. Complement
deficiencies or dysfunctions have been shown to be associated
with diseases such as atypical hemolytic uremic syndrome
(aHUS), age-related macular degeneration (AMD), paroxysmal
nocturnal hemoglobinuria (PNH), systemic lupus erythematosus
(SLE), C3 glomerulopathy (C3G), and other kidney diseases
(3, 4). Furthermore, complement activation contributes to several
diseases and pathological conditions such as renal replacement
therapy (5–7), cancer (8), hypersensitivity reactions (9, 10), and
neurological conditions (11).
The complement system is activated via an enzymatic cascade
reaction and has three different activation pathways, namely
the classical pathway (CP), the lectin pathway (LP), and the
alternative pathway (AP). Complement activity for each of these
pathways depends on the expression and function of a large
number of complement proteins. The CP is mainly initiated by
immune complexes binding to C1q leading to activation of C1r
and C1s, but can also be activated in an antibody independent
manner like C1q binding to C-reactive protein. The LP is initiated
by the binding of mannose-binding lectin (MBL), ficolins, or
collectins to sugars or acetylated compounds resulting in the
activation of the MBL-associated serine protease (MASP)-1 and
MASP-2. Recently it has also been shown that the LP can
be activated by naturally occurring antibodies, underscoring
the overlap and cross-talk between the pathways (12). LP and
CP activation both lead to the cleavage of C4 and C2, and
subsequently to the generation of C4b2a, the C3-convertase.
Abbreviations: aHUS, Atypical haemolytic uremic syndrome; AMD, Age-related
macular degeneration; AP, Alternative pathway; C1-INH, C1-inhibitor; C4bp,
C4b-binding protein; C3G, C3 glomerulopathy; CP, Classical pathway; IQR,
Interquartile range; LP, Lectin pathway; MAC, Membrane attack complex;
MASP, MBL-associated serine protease; MBL, Mannan-binding lectin; MBL-
LP, MBL-induced lectin pathway; PNH, Paroxysmal nocturnal hemoglobinuria;
SLE, Systemic lupus erythematosus; SNP, Single-nucleotide polymorphism; TP,
Terminal pathway.
Furthermore, C1-inhibitor (C1-INH) regulates the activity of
the recognition complexes, while C4b-binding protein (C4bp)
functions as a cofactor for factor I-mediated cleavage of C4b.
Initiation of the AP occurs via spontaneous hydrolysis of C3
into C3(H2O) or by the binding of C3b to altered surfaces.
Factor D cleaves factor B when the latter is complexed with
C3b, creating the C3-convertase of the AP, C3bBb. In addition,
this C3-convertase is stabilized by properdin, the only positive
regulator of the complement system. Regardless of the initial
pathway, complement activation can lead to the initiation of
the terminal pathway (TP) and thereby the generation of C5-
convertase, which cleaves C5 in C5a, a powerful anaphylatoxin,
and C5b. Next, C5b binds C6 which then attaches to a surface
and interacts with C7, C8, and C9 to form the membrane attack
complex (MAC/C5b-9) (13, 14). If there is no surface present,
C5b6 will bind to C7, C8 and C9 together with the control
proteins vitronectin and clusterin in the fluid-phase and thereby
the soluble form of the terminal complement complex, sC5b-
9, is formed. To prevent unintended complement activation
the system is kept under control by a variety of regulators.
The major regulators of the AP are the plasma proteins factor
H and factor I. Factor H inhibits complement activation by
accelerating the decay of the C3bBb convertase of the AP and
by providing cofactor activity for factor I-mediated cleavage
of C3b.
Both age and sex are known to influence and significantly
impact the immune system (15). Females and males have
distinct innate and adaptive immune responses (16). Moreover,
they also differ in their immunological responses to self and
foreign-antigens (17). Sex-based immunological differences can
be found in various species (18). In general, the immune
response seems to be stronger in females than in males (15).
These immunological sex differences are thought to arise from
discrepancies in hormones, genetic factors and environmental
mediators. Notably, these sex-related differences in the immune
system could give insight into the epidemiology and etiology
of autoimmune and infectious diseases (15). Likewise, aging is
associated with a progressive decline in immunity. The impact
of aging on adaptive immunity is well accepted (19). However,
less certainty exists on the effect of aging on innate immunity
(20). Impaired function of neutrophils and macrophages as
well as reduced interaction between dendritic cells and T cells,
suggest also a decline in innate immune function (21). As a
result of impaired immune function, the ability of elderly to
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respond to microorganisms is diminished and the number of
infectious disease is increased (22). Also the increased incidence
of autoimmune diseases might be related to altered immunity in
elderly (23).
In the current era of personalized medicine combined with
the recent success of complement inhibitors in clinical trials,
it is essential to identify the influence of sex and age on
the complement system. Given that complement therapeutics
are an effective treatment for complement-mediated diseases,
individuals will need different doses in order to efficiently
block the complement system depending on the concentrations
and functional activity of the complement components. Factors
influencing the levels could be e.g., sex and age. Thus,
the aim of the present study was to explore the effect
of age and sex on the complement system in a healthy
Caucasian population by performing functional and quantitative
complement analyses. The current study also enables us to better
understand the complement system in different physiological
conditions.
MATERIALS AND METHODS
Serum Samples
Serum samples were obtained from a population of 120 healthy
Caucasian individuals from Norway, registered as blood donors.
From each sex, 12 samples were obtained per age decade between
20 and 70. Sixty females with a mean age of 44.7 years (range: 20–
69 years) and 60 males with a mean age of 45.1 years (range: 20–
65 years) were included. Serum samples obtained were directly
aliquoted and stored at−80
◦
C.
FIGURE 1 | Complement pathway activity according to sex. The activity of the
classical pathway (CP), alternative pathway (AP), and MBL-induced lectin
pathway (MBL-LP) was measured in 120 Caucasian healthy subjects, of which
60 males and 60 females. The solid lines indicate the median values in each
group. The differences between males and females was assessed by the
Mann Whitney test (***P < 0.001). CP/AP activity is referred to the left Y-axis in
linear scale whereas MBL-LP activity is referred to the right Y-axis in a
logarithm scale.
Assessment of Pathway Activity in Normal
Human Serum Samples
The complement kit (Complement System Screen Wieslab R©,
Eurodiagnostica, Malmö, Sweden) for assessment of CP, LP, and
AP activity was used according to the manufacturer’s instructions
(24, 25). In brief, strips of wells for CP were coated with IgM,
strips for MBL-LP were coated with mannan and strips for AP
were coated with LPS. Sera were diluted 1/101 for the CP and
MBL-LP assays and 1/18 for the AP assay in specific buffers
to ensure that activation of only the actual pathway occurred,
and were incubated for 1 h at 37◦C. After washing, alkaline
phosphatase-conjugated anti-human C5b-9 was added before
incubation at room temperature for 30min. Additional washing
was performed, substrate was added and the wells were incubated
for 30min. Finally, absorbance values were read at 450 nm. In
each assay standard positive and negative control sera, provided
in the kit as lyophilized material and reconstituted with distilled
water, were assessed. The positive standard serum was a pool of 5
sera from healthy individuals and the negative control consisted
of sera heat-inactivated at 56◦C for 20min. Complement activity
was calculated using the following formula: activity = 100% x
(mean A450 (sample)–mean A450 (negative control) / (mean
A450 (standard serum) - mean A450 (negative control). Samples
as well as standard serum and negative control serum were tested
in duplicate.
Serum Complement Concentrations
Assessment of MBL concentrations was performed using a
commercial MBL ELISA obtained from BIOPORTO Diagnostics
A/S (Hellerup, Denmark) and performed according to the
manufacturer’s instructions. C1q, C4, C3, and C1-inhibitor
concentrations were assessed using nephelometry on a
BN-Prospec, with validated diagnostic protocols provided
by the manufacturer (Siemens Healthcare Diagnostics,
Marburg, Germany), calibrated using a complement standard
serum provided by the manufacturer. C2 and factor B were
measured using rocket-immunoelectrophoresis as described by
Sjöholm et al. (26–28). Properdin and Factor D were assessed
by electroimmunoassay as previously described (29, 30).
Concentrations of C2, factor B, properdin and factor D were
expressed in arbitrary units (% of pooled human serum).
MASP-1, MASP-2, Ficolin-2, and Ficolin-3 levels were
determined using in-house ELISAs. For all in house ELISA’s
(Leiden University Medical Center, Leiden, the Netherlands)
a standard protocol was used. In brief, Nunc Maxisorb
plates (Nunc, Roskilde, Denmark) were coated using coating
buffer (100mM Na2CO3/NaHCO3, pH 9.6), for 16 h at
room temperature. After each step, plates were washed
three times with PBS containing 0.05% Tween 20. Residual
binding sites were blocked by incubation with PBS containing
1% BSA. Unless otherwise indicated, all subsequent steps
were incubated in PBS containing 0.05% Tween 20 and 1%
BSA, for 1 h at 37◦C. Detection antibodies were conjugated
to digoxigenin (Dig) using Dig-3-O-methylcarbonyl-ε-
aminocaproic acid-N-hydroxysuccinimide ester (from
Boehringer Mannheim, Mannheim, Germany), followed
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FIGURE 2 | Differences in complement components between sexes. In 120 subjects, consisting of 60 males and 60 females complement levels of (A) C3, (B)
Properdin, (C) Factor D, (D) MBL, (E) Ficolin-3 were measured. The solid lines indicate the median values in each group. The differences between males and females
was assessed by the Mann Whitney test (*P < 0.05, **P < 0.01, ***P < 0.001).
by detection using HRP-conjugated rabbit anti-Dig Abs
(Fab, from Boehringer Mannheim). Enzyme activity of HRP
was detected using 2,2′-azino-bis(3-ethylbenzthiazoline-
6-sulfonic acid) (Sigma) and absorption was measured
at 415 nm.
In more detail, for the detection of MASP-1 and MASP-
2, polyclonal antibodies were raised in rabbits against the
recombinant protease domain of MASP-1 and MASP-2,
respectively, kindly provided by Dr. Peter Gál (31). However,
based on the specificity of the anti-MASP-1 antibody it is likely
that the results from this ELISA represent the sum of MASP-1
and MASP-3 levels. ELISA plates were coated with rabbit
IgG anti-MASP-1 and rabbit IgG anti-MASP-2, respectively.
Patient samples were incubated in GVB/NaCl/EDTA (Veronal-
buffered saline containing 0.05 % Tween-20, 0.1 % gelatine,
0.5M NaCl, 10mM EDTA; pH 7.5), followed by detection
using the same antibodies, which were conjugated as described
above. Results were expressed in arbitrary units per ml using a
standard line of serially diluted pooled normal human serum
for calibration. For detection of ficolin-2, a similar protocol
was followed using mouse monoclonal antibody GN5. Results
were expressed in pg/ml as described previously (32). Both GN5
and 4H5 were kindly provided by dr. T. Fujita, Department of
Immunology, Fukushima Medical University, Fukushima,
Japan). For detection of ficolin-3, the standard ELISA
protocol was followed and the mouse monoclonal antibody
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4H5 was used for both coating and detection. Results were
expressed in arbitrary units/ml using pooled human serum for
calibration.
C4bp, C5, C8, and C9 were measured by ELISA as previously
described (33–35). C6 and C7 were measured using an in-house
ELISA assay as previously described (36). In brief, wells were
coated with an in house mouse monoclonal antibody against C6
(WU 6-4, Hycult, Uden, NL) and with an in house polyclonal
antibody against C7. For the detection, respective biotinylated
polyclonal antibodies were used. For the set-up of the ELISA,
purified C6 or C7 (Cytotech, San Diego, CA, USA) were used to
calibrate human serum as a standard.
The standards used in the different assays were not calibrated
to the official European complement standard.
Statistics
Statistical analysis was performed using IBM SPSS 22.0 (IBM
Corporation, Chicago, IL, USA). Concentrations of complement
proteins and pathway activity were presented as median with
interquartile range [IQR]. Differences between sexes were
assessed with the Mann Whitney U test. Correlation between
age and complement proteins or pathway activity was evaluated
using the Spearman Rank correlation coefficient (r). Univariate
and subsequent multivariate linear regression analysis were
performed to identify independent determinants of complement
pathway activity. Multivariate analysis models were constructed
using backward selection (Pout > 0.05) including complement
proteins that were associated significantly (P < 0.05) with
complement pathway activity in univariate analysis. P < 0.05
were considered statistically significant.
RESULTS
Differences Between Males and Females in
Complement Pathway Activity and
Components
CP, MBL-LP, and AP activity were determined by deposition of
C5b-9 in serum samples from 60 males and 60 females. CP and
MBL-LP activity were similar in both sexes (Figure 1). However,
AP activity was significantly lower in females compared to males.
The median AP activity for females was 69.5% compared with
81.0% for males (P < 0.001, Figure 1).
In accordance, the levels of C3 and properdin were also
significantly lower in women in comparison with men. Median
C3 concentrations in females were 1.37 mg/mL [1.19–1.59]
compared to 1.51 mg/mL [1.34–1.76] in males (P = 0.001,
Figure 2A), whereas median levels of properdin in females were
107% [91–128] vs. 120% [98–138] inmales (P= 0.03, Figure 2B).
Conversely, serum concentration of factor D showed an opposite
pattern (P < 0.001, Figure 2C), since levels were significantly
higher in females (140%, IQR: 115%−200%) than in males
(100%, IQR: 82%−137%). Males had higher levels of serumMBL
in relation to female subjects. Median MBL concentrations were
533 ng/mL [142–1,076] and 843 ng/mL [289–1,646] in females
and males, respectively (P = 0.03, Figure 2D). Likewise, female
subjects also had significantly lower levels of ficolin-3 compared
TABLE 1 | Levels of complement components that did not significantly differ
between the sexes.
Component Male Female P-value
C1q (in mg/L) 141 [1.28–1.49] 136 [125–142] 0.12
C1-INH (in mg/mL) 0.28 [0.25–0.30] 0.26 [0.23–0.30] 0.07
Ficolin-2 (in pg/mL) 1680 [1160–2235] 1568 [1063–2403] 0.64
MASP-1 (in AU/mL) 700 [603–906] 749 [611–919] 0.53
MASP-2 (in AU/mL) 856 [650–1620] 799 [609–1121] 0.14
C2 (in AU/mL) 126 [104–140] 123 [107–134] 0.58
C4 (in mg/mL) 0.28 [0.20–0.32] 0.23 [0.19–0.29] 0.07
C4bp (in µg/mL) 214 [197–248] 206 [177–245] 0.30
Factor B (in AU/mL) 103 [93–118] 98 [88–120] 0.22
C6 (in µg/mL) 44.6 [31.8–65.6] 37.9 [25.3–54.9] 0.08
The current table displays levels of components that were not significantly different.
Values are presented as median and interquartile range [IQR]. P-values represent the
difference between males and females tested by Mann Whitney test. Abbreviations: C1-
INH, C1-inhibitor; MASP, MBL-associated serine protease; C4bp, C4b-binding protein.
The standards used in the different assays were not calibrated to the official European
complement standard.
to male subjects, with a median of 830 AU/mL [676–1,034]
and 1042 AU/mL [883–1,192] in females and males, respectively
(P = 0.001, Figure 2E).
The rest of the components measured did not differ between
females and males (Table 1). In line with CP activity, serum
levels of C1q, C4, C2, C1-INH, and C4bp did not differ between
the sexes (Table 1). Furthermore, despite the fact that MBL-LP
activity was not significantly different between the sexes, a trend
was still seen for lower activity in females compared to males.
Additionally, 17% of the males were MBL deficient (0% MBL-LP
activity) whereas in females this was 23%. The threshold of MBL
concentration to result in zero activity was 130 ng/mL. The other
components from the LP such asMASP-1, MASP-2 and Ficolin-2
did not differ between both sexes (Table 1).
Quantification of the terminal complex components revealed
that all these components, except C6, were significantly lower in
female subjects compared to male subjects (P < 0.05, Figure 3).
The presented data show that in women, levels were 53, 15,
59, and 14% lower, for C5, C7, C8, and C9, respectively. For
C8, concentrations above 50µg/ml were exclusively observed in
males (65% of male subjects had concentrations of C8 above
50µg/ml).
Age-Related Changes in Complement
Pathway Activity and Components
Next, we determined the effect of age on the complement system
by correlating complement components and activity with age
in 120 healthy individuals with a mean age of 45 years ± 13.5,
ranging from 20 to 69 years old. Linear regression analysis
demonstrated a significant age-related effect for CP and AP
activity, but not for the MBL-LP activity (data not shown).
In accordance, age significantly correlated with CP activity
(r = 0.42, P < 0.001, Figure 4A) and AP activity (r = 0.30,
P< 0.001, Figure 4B), but not withMBL-LP activity (Figure 4C).
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FIGURE 3 | Differences in terminal pathway components between sexes. In 120 subjects, consisting of 60 males and 60 females, complement levels of (A) C5, (B)
C7, (C) C8, and (D) C9 were measured. The solid lines indicate the median values in each group. The differences between males and females was assessed by the
Mann Whitney test (*P < 0.05, ***P < 0.001).
However, when the twenty-five oldest individuals (mean age
62 ± 2.3 years) were compared to the twenty-five youngest
individuals (mean age 26 ± 3.3 years) significant differences
were observed in all pathways: higher CP activity (106 vs. 91%,
P < 0.001), lower MBL-LP activity (35 vs. 60%, P = 0.01) and
higher AP activity (83 vs. 74%, P = 0.01). Subsequently, we
analyzed the effect of age on the concentration of the different
complement components and factors. Regardless of statistics, a
correlation coefficient below 0.3 was not perceived as clinically
relevant (37). A significant effect of age was observed for C1-
INH, factor D, C5, C8, and C9 levels (Figure 5). C1-INH showed
an age-related rise (Figure 5A, r = 0.30, P = 0.001), whereas
factor D (Figure 5B, r = −0.32, P = 0.001) levels decreased
with age. Consistent with the age-related increase in CP and
AP activity, levels of C5 (Figure 5C, r = 0.40, P < 0.001), C8
(Figure 5D, r = 0.43, P < 0.001) and C9 (Figure 5E, r = 0.31,
P = 0.001) positively correlated with age. The comparison
between the oldest and youngest twenty-five individuals showed
that C5, C8, and C9 levels increased by 47% (P < 0.001),
60% (P < 0.001), and 24% (P = 0.001), respectively, with age.
Finally, if we correct for sex, the impact of age on CP and
AP activity remains significant. However, the age-related effect
on AP is predominantly found in female subjects (females:
r = 0.35, P = 0.05), whereas the effect of age on CP activity
was predominantly found in male subjects (males: r = 0.61,
P < 0.001).
The Relationship Between Complement
Components and Pathway Activity
To better understand the determinants of complement activity
of the different pathways, we related individual complement
components with their respective complement pathway
(Tables 2–4). CP activity correlated significantly with C2 levels
(Table 2, r = 0.51, P < 0.001), whereas MBL-LP activity
significantly correlated with MBL concentrations (Figure 6,
Table 3, r = 0.89, P < 0.001). Furthermore, for AP activity
significant correlations were seen with properdin (Table 4,
r = 0.35, P < 0.001), factor B (Table 4, r = 0.51 P < 0.001) and
C3 (Table 4, r = 0.42, P < 0.001). In addition, we correlated
terminal pathway components with complement activity of the
different pathways (Table 5). CP activity correlated significantly
with C5 (Table 5, r = 0.39, P < 0.001) and C9 (Table 2,
r = 0.42, P < 0.001), while AP activity correlated with C5
(Table 5, r = 0.56, P < 0.001), C8 (Table 5, r = 0.43, P < 0.001)
and C9 (Table 5, r = 0.38, P < 0.001). MBL-LP activity did
not correlate with any of the terminal pathway components
(Table 5). However, besides the correlation between individual
complement components with their respective complement
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FIGURE 4 | Correlations between complement pathway activity and age. In
120 healthy subjects age was correlated to the activity of the (A) classical
pathway (CP), (B) alternative pathway (AP) and (C) MBL-induced lectin
pathway (MBL-LP). These correlations were evaluated using the Spearman
Rank correlation coefficient. P < 0.05 were considered to be statistically
significant.
pathway, there were also correlations between different
complement components with each other. The latter could form
a possible confounder for the pathway analysis. Subsequently,
we performed a multivariate linear regression analysis and
found that levels of C2, C1-INH, and C5 were independent
determinants of CP activity (model R2 = 0.46, Table 6), whereas
MBL and MASP-2 were independent determinants of MBL-LP
activity (model R2 = 0.66, Table 6). Moreover, the multivariate
linear regression analysis demonstrated that only C3, factor B
and C5 were independent determinants of AP activity (model
R2 = 0.46, Table 6).
DISCUSSION
In the current study, we demonstrate in a healthy Caucasian
population that sex and age significantly impact the complement
system. Sex-related analysis revealed that females have lower AP
activity and lower AP and LP complement components, with an
exception for factor D. In addition, females showed significantly
lower levels of C3 and terminal pathway components. These
results demonstrate that females have significantly lower
complement activity and levels of complement components
compared to males. Furthermore, age-related analysis showed
that aging is associated with an enhanced functional activity
of the CP and the AP. Correspondingly, terminal pathway
components levels increased with age. Lastly, we analyzed
the determinants of functional complement pathway activity,
by relating individual complement components with their
respective complement pathway. In healthy individuals, CP
activity was determined by C2, C1-INH, and C5, MBL-
LP activity by MBL and AP activity by C3, factor B and
C5. These results support the relevance of age- and sex-
matched control cohorts in studies related to the complement
field, including the assessment of reference values used
in clinical laboratory diagnostics. Moreover, these results
suggest that age and sex should be taken into account in
complement-related pathology as well as in complement-targeted
therapies.
For the majority of complement components the liver is
the predominant source of production, and production of
complement proteins can be regulated by an acute phase response
(38). Other main production sites includes peripheral blood
mononuclear cells which are responsible for the production of
C1q, properdin and C7, adipocytes which produce factor D and
the lungs where ficolin-3 is mainly produced (39, 40). In fact,
most tissues and inflammatory cells are able to produce various
complement proteins, e.g., upon stimulation with cytokines (40).
Additionally, genetic environmental and lifestyle factors such
as obesity and smoking also influence complement levels (41–
43). Multiple complement deficiencies have been described and
associated with pathology (44). In addition, single-nucleotide
polymorphisms (SNP) can strongly affect the concentration
and/or function of various complement proteins, as have been
well-documented for e.g., MBL (45, 46). Yet, limited studies have
investigated the influence of sex and age on the complement
system (47–49).
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FIGURE 5 | Correlation of complement proteins with age. In 120 healthy subjects age was correlated to the concentration of (A) C1-INH, (B) Factor D, (C) C5. (D)
C8, and (E) C9. These correlations were evaluated using the Spearman Rank correlation coefficient. P < 0.05 were considered to be statistically significant.
The immune system varies between males and females and
differences in innate and adaptive immunity have already been
demonstrated. At least two factors are known to explain the
influences of sexual dimorphism in immunity: genetics (e.g., the
X chromosome) and hormonal differences (50). Remarkably, the
X chromosome contains genes that encode for several proteins
related to immune response such as toll-like receptors and
interleukins. Moreover, properdin is encoded on the short arm
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TABLE 2 | Correlations between classical pathway functional activity, complement levels, and age.
CP C1q C2 C4 C3 C1-INH Age
CP – – – – – – 0.42
P < 0.001
C1q 0.20 – – – – – −0.04
P = 0.03 P = 0.67
C2 0.51 0.30 – – – – 0.28
P < 0.001 P = 0.001 P = 0.002
C4 0.11 0.29 0.32 – – – 0.07
P = 0.27 P = 0.002 P = 0.001 P = 0.47
C3 0.20 0.37 0.45 0.65 – – 0.001
P = 0.03 P < 0.001 P < 0.001 P < 0.001 P = 0.99
C1-INH 0.24 0.23 0.52 0.44 0.42 – 0.30
P = 0.009 P = 0.01 P < 0.001 P < 0.001 P < 0.001 P = 0.001
C4bp 0.24 0.28 0.44 0.29 0.39 0.38 0.13
P = 0.009 P = 0.002 P < 0.001 P = 0.002 P < 0.001 P < 0.001 P = 0.17
Spearman’s correlation was performed and data are presented as correlation coefficient and corresponding P-value. Significant correlations are highlighted. C1-INH, C1-inhibitor; CP,
classical pathway activity; C4bp, C4b-binding protein.
TABLE 3 | Correlations between MBL-lectin pathway functional activity, complement levels, and age.
MBL-LP MBL MASP-2 MASP-1 C2 C4 C3 C4bp Age
MBL-LP – – – – – – – – −0.16
P = 0.09
MBL 0.89 – – – – – – – −0.16
P < 0.001 P = 0.09
MASP-2 0.21 0.09 – – – – – – −0.03
P = 0.025 P = 0.32 P = 0.72
MASP-1 0.09 0.06 0.29 – – – – – −0.20
P = 0.33 P = 0.53 P = 0.001 P = 0.03
C2 −0.08 −0.07 −0.06 0.06 – – – – 0.28
P = 0.39 P = 0.44 P = 0.56 P = 0.52 P = 0.002
C4 −0.06 −0.07 0.05 −0.01 0.32 – – – 0.07
P = 0.53 P = 0.46 P = 0.63 P0.92 P = 0.001 P = 0.47
C3 −0.05 0.12 0.13 0.14 0.45 0.65 – – 0.001
P = 0.54 P = 0.19 P = 0.17 P = 0.12 P < 0.001 P < 0.001 P = 0.99
C4bp −0.08 −0.02 0.18 −0.04 0.44 0.29 0.39 – 0.13
P = 0.38 P = 0.83 P = 0.05 P = 0.66 P < 0.001 P = 0.002 P < 0.001 P = 0.17
C1-INH 0.08 0.15 0.03 −0.05 0.52 0.44 0.42 0.38 0.30
P = 0.12 P = 0.12 P = 0.77 P = 0.59 P = <0.001 P < 0.001 P < 0.001 P < 0.001 P = 0.001
Spearman’s correlation was performed and data are presented as correlation coefficient and corresponding P-value. Significant correlations are highlighted.C1-INH, C1-inhibitor; C4bp,
C4b-binding protein; MBL, mannose-binding lectin; MBL-P, MBL-induced pathway activity; MASP, MBL-associated serine protease.
of the X chromosome (51). However, in our study, females had
lower properdin levels than males, demonstrating once more
that genetic factors do not solely determine the concentration
of the components. In addition, sex hormones are known to
influence innate and adaptive immunity. The majority of the cells
from innate and adaptive immunity express estrogen receptors
(52). However, data on the influence of sex on the complement
system remains limited. A study by Roach et al. demonstrated
that in children (age range 1–19 years) there were differences
in several complement components between boys and girls (49).
However, the differences found in this study were age-dependent.
Troldborg et al. studied complement proteins restricted to the
lectin pathway and showed comparable results to ours, showing
that female have lower complement levels than males (53).
Previously, an animal study demonstrated the influence of sex
hormones on the complement system by injecting estrogen and
testosterone in healthy and castrated mice from both sexes (54).
Mice treated with testosterone showed increased late acting
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TABLE 4 | Correlations between alternative pathway functional activity, complement levels, and age.
AP Properdin Factor B Factor D Age
AP – – – – 0.30
P = 0.001
Properdin 0.35 – – – −0.01
P < 0.001 P = 0.89
Factor B 0.51 0.24 – – 0.27
P < 0.001 P = 0.01 P = 0.003
Factor D 0.13 −0.02 0.05 – −0.32
P = 0.17 P = 0.85 P = 0.59 P = 0.001
C3 0.42 0.52 0.50 0.06 0.001
P < 0.001 P < 0.001 P < 0.001 P = 0.48 P = 0.99
Spearman’s correlation was performed and data are presented as correlation coefficient and corresponding P-value. Significant correlations are highlighted. AP, alternative pathway
activity.
complement activity while mice treated with estrogen showed
diminished activity (48). In accordance, a recent animal study
demonstrated lower complement functionality in female mice
due to lower levels of terminal complement components (47).
This has been a reason for our group to perform complement-
related animals experiments solely in male rodents (55, 56).
Altogether, these results in rodents are in line with our findings
that females have lower terminal complement components and
lower functional activity. In our study, only Factor D was
significantly higher in woman. A possible explanation could
be a higher amount of adipose tissue in woman than in men,
resulting in enhanced production. Unfortunately, factor H and
factor I were not determined in our cohort. Previous studies
did not find significant differences between sexes in factor H
levels in adults (57). In addition, very recent work did not
observe an effect of sex or age in factor H levels in children
(54). However, since we observed a lower AP functional activity
in females, a possible explanation for this difference could be
higher levels of factor H and/or factor I. Nonetheless, the clinical
consequences of these differences remain to be elucidated. Yet,
some clues already indicate that sex could form a possible
confounder in complement-mediated diseases. For instance, in
a cohort of healthy people, low MBL levels were associated
with cardiovascular disease, however this association was seen
only in men and not in women (58). Moreover, in a study
of AMD, distinct alterations were shown between the sexes in
levels of AP components (59). Thus, more studies are needed to
clarify the significance of sexual dimorphism on the complement
system. In the future, these shortcomings could be addressed
by studying the complement system in transsexual subjects
undergoing hormonal replacement therapy. Nevertheless, an
important question that remains is: should we treat women and
men equally when it comes to complement therapeutics?
In the early phase of life, innate immunity plays a fundamental
role since adaptive immunity is still under development, whereas
during adolescence this is reversed (60). Immunity undergoes
severe deterioration with age (15, 60). Previous studies showed
that both for innate and adaptive immunity, the function
reduces with age (22, 61). Whether this decline in innate
FIGURE 6 | Correlation between MBL-LP activity and MBL levels. In 120
healthy subjects MBL levels were correlated to the activity of the MBL-LP (%).
This correlation was evaluated using the Spearman Rank correlation
coefficient. A p < 0.05 was considered to be statistically significant.
immune function is also true for the complement system was
still unknown. In a Japanese healthy cohort, C3 levels varied
according to different age ranges, however not in a continuous
way (62). Certain LP components were also investigated in a large
population and showed MBL levels are reduced in adults when
compared to children (63) Previously, in a cohort of centenarians,
MBL levels were reported to be reduced compared to the general
population (64). However, this reduction was based on a higher
prevalence of mbl2 gene mutations, suggesting a beneficial role
of intermediate levels of MBL for longevity. In our study, we
found that age had a minor effect on MBL-LP activity, but
significantly enhanced the activity of CP and AP. Accordingly,
in an earlier study in healthy subjects aged between 20 and 69
years old, increased CH50 activity during aging was observed
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TABLE 5 | Correlations between terminal pathway components, functional pathway activity and age.
AP CP MBL-LP C5 C6 C7 C8 Age
AP – – – – – – – 0.30
P = 0.001
CP 0.44 – – – – – – 0.42
P < 0.001 P < 0.001
MBL-LP 0.02 0.04 – – – – – −0.16
P = 0.87 P = 0.69 P = 0.09
C5 0.56 0.39 0.06 – – – – 0.40
P < 0.001 P < 0.001 P = 0.51 P < 0.001
C6 0.07 −0.03 −0.05 0.18 – – – 0.18
P = 0.44 P = 0.74 P = 0.61 P = 0.04 P = 0.04
C7 −0.09 −0.05 −0.01 0.10 0.32 – – 0.04
P = 0.34 P = 0.57 P = 0.94 P = 0.28 P < 0.001 P = 0.65
C8 0.43 0.27 0.00 0.59 0.20 0.22 – 0.43
P < 0.001 P = 0.003 P = 0.99 P < 0.001 P = 0.02 P = 0.01 P < 0.001
C9 0.29 0.42 −0.07 0.40 0.12 0.04 0.48 0.31
P = 0.001 P < 0.001 P=0.47 P < 0.001 P=0.18 P=0.65 P < 0.001 P=0.001
Spearman’s correlation was performed and data are presented as correlation coefficient and corresponding P-value. Significant correlations are highlighted. AP, alternative pathway
activity, CP, classical pathway activity; MBL-LP, Mannose-Binding Lectin-induced pathway activity.
TABLE 6 | Univariate and multivariate determinants of functional complement
pathway activity.
Univariate Multivariate
Standardized β P-value Standardized β P-value
ALTERNATIVE PATHWAY ACTIVITY
Factor B 0.48 <0.001 0.28 <0.001
Properdin 0.35 <0.001
C3 0.50 <0.001 0.26 0.001
C5 0.51 <0.001 0.37 <0.001
C8 0.36 <0.001
C9 0.35 <0.001
CLASSICAL PATHWAY ACTIVITY
C1q 0.20 0.04
C2 0.63 <0.001 0.62 <0.001
C3 0.19 0.04
C1-INH 0.20 0.03 −0.14 0.04
C4bp 0.24 0.01
C5 0.39 <0.001 0.25 0.001
C8 0.22 0.02
C9 0.30 0.001
MBL PATHWAY ACTIVITY
MBL 0.79 <0.001 0.78 <0.001
MASP-2 0.23 0.01 0.18 0.001
Multivariate linear regression analysis was performed to identify independent determinants
of complement pathway activity. All variables described in Tables 2–5 were tested,
only variables with P < 0.05 in the univariate analysis are shown. Multivariate analysis
models were constructed using backward selection (Pout > 0.05) including complement
proteins that were associated significantly (P < 0.05) with complement pathway activity
in univariate analysis. C1-INH, C1-inhibitor; C4bp, C4b-binding protein; MBL, Mannose-
Binding Lectin; MASP-2, MBL-associated serine protease 2.
and associated with increased levels of individual components
of the CP (65). Moreover, in line with the enhanced functional
activity of CP and AP, the levels of terminal pathway components
C5, C8, and C9 also raised with age. However, an important
limitation of our results is that our study design is cross-sectional
and not longitudinal. Accordingly, our study is unable to
discriminate between true age-related changes or better survival
due to evolutionary advantages. Possible explanations for the
aging immune system could be epigenetic changes, metabolic
changes, changes in protein production and degradation and
accumulation of senescence cells. Finally, the increased levels of
terminal pathway components with age could be a mechanism
to compensate for the impaired clearance of pathogens and
apoptotic cells due to lower cellular immunity (66).
The current findings help to become conscious of changes
in complement function during physiological conditions.
Furthermore, the data obtained provide insight in the complex
teamwork of all the different complement proteins to achieve the
end goal, i.e., the production of the membrane attack complex
upon complement activation. To further study the contribution
of each individual component to their respective pathway(s) we
first correlated individual complement components with their
complement pathway function. However, since complement
components also correlated with each other, this could cause
a potential confounder. Thus, we next performed multivariate
regression analysis, to correct for other components and
confounders. In this analysis, MBL and MASP-2 levels were
independent determinants of MBL-P activity. For the CP activity,
C2 and C5 levels were the strongest determinants. In accordance,
C2 has previously been described as the rate-limiting factor
in the CP activation (67). In addition, C1-INH was also an
independent determinant of CP activity, however with a negative
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value, confirming that C1-INH acts as a negative regulator of CP
activation (68, 69). Furthermore, AP activity was dependent on
C3, factor B and C5. Factor D has previously been described as
the rate-limiting step of the AP, however the current study does
not confirm these results (67, 70). Our studies confirm the key
role of C5 as a rate limiting step for activation of the terminal
pathway of complement, both via the CP and via the AP.
Expression of complement genes and complement function
is at least partially genetically determined. In the present study,
the function of the MBL pathway was strongly determined by
the concentration of MBL, of which the expression of functional
molecules is largely genetically controlled by a number of SNP
in the promoter and coding region (45, 71). Our data also
show that the concentration of factor B is positively correlated
to the concentrations of C4 (r = 0.39) and C2 (r = 0.42),
suggesting co-regulation of the genes involved, which are located
in close proximity to each other in the MHC class III region
at chromosome 6 (72). Similarly, expression of C5 and C8 is
strongly correlated, suggesting co-regulation of expression of
genes for C5 and C8-gamma, located at chromosome 9q33.
The present study focused on complement function and
individual component concentration. It was out of the scope
to investigate complement activation products reflecting basic
ongoing in vivo complement activation. In contrast to differences
found in native component concentrations, we have previously
shown that a number of complement activation products did
not differ between female and male blood donors indicating
that the degree of physiologic activation not necessarily is
reflected by the different individual component concentrations
(73). Furthermore, the concentration of activation products did
not differ between the age groups divided in decades from 20
to 70 years (unpublished data). Others have shown that there is
an individual diurnal variation of complement components and
anaphylatoxins dependent of sleep (74).
We acknowledge that the present study has limitations.
Although our cohort includes a variety of subjects in different
age ranges, one limitation is the absence of age below and above
blood donor acceptance (i.e., 20 and 69 years). Additionally, we
did not have genetic and lifestyle background from the subjects
of the study, which could add valuable information. However, all
donors were accepted as blood donors according to the health
criteria for donating blood at the hospital, implying that they
represent the health part of the population. Furthermore, the
complement system comprises over more than 50 proteins and
we were therefore unable to determine all complement proteins.
Concerning LP, the current study only measured functional
activity of MBL and not from the other initiators such as
ficolins and collectins. Finally, the standards used in the different
assays were not calibrated to the official European complement
standard. However, this would not change our conclusions, just
the absolute values. On the other hand, strengths include the
number of complement proteins determined, the combination of
quantitative and functional analysis, the population size and the
in-depth performed statistical analysis.
In conclusion, there are important sex- and age-related
differences in the complement system. These changes should be
taken into account when studying complement-related diseases.
Furthermore, complement therapies that are now reaching the
clinical phase should be tested for the different sexes and age
ranges since different complement profiles might affect the
efficiency of a therapy.
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